Editas Medicine (EDIT) Gains from Sales and Divestitures (2016 - 2023)
Editas Medicine (EDIT) reported Gains from Sales and Divestitures of $210701.0 for Q2 2023, down 9.46% year-over-year from $232718.0 in Q2 2022, and up 44.11% quarter-over-quarter from $146209.0 in Q1 2023.
Editas Medicine (EDIT) Gains from Sales and Divestitures (2016 - 2023) Analysis & Trends
Editas Medicine (EDIT) has 8 years of Gains from Sales and Divestitures data on file, last reported at $210701.0 in Q2 2023.
- Gains from Sales and Divestitures for Q2 2023 came in at $210701.0, down 9.46% year-over-year; the trailing twelve-month figure through Jun 2023 was $210701.0 (down 9.46% YoY), and the FY2022 annual result was $286642.0, up 7.25% from the prior year.
- Gains from Sales and Divestitures advanced to $210701.0 in Q2 2023 per EDIT's latest filing, from $146209.0 in the prior quarter.
- Over five years, Gains from Sales and Divestitures peaked at $304638.0 in Q4 2020 and troughed at $18000.0 in Q1 2019.
- A 5-year average of $179748.3 and a median of $200888.0 in 2021 frame the typical range for Gains from Sales and Divestitures.
- The sharpest annual moves came in 2019 and 2020: Gains from Sales and Divestitures plunged 82.7% in 2019, then soared 1085.52% in 2020.
- A 5-year view of Gains from Sales and Divestitures shows it stood at $99919.0 in 2019, then jumped by 204.88% to $304638.0 in 2020, then dropped by 12.27% to $267268.0 in 2021, then rose by 7.25% to $286642.0 in 2022, then decreased by 26.49% to $210701.0 in 2023.
- Business Quant data shows EDIT's Gains from Sales and Divestitures at $210701.0 in Q2 2023, $146209.0 in Q1 2023, and $286642.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Editas Medicine | 262.77 Mn | 262.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 210,701.00 |
| Jun 30, 2023 | 210,701.00 |
| Mar 31, 2023 | 146,209.00 |
| Mar 31, 2023 | 146,209.00 |
| Dec 31, 2022 | 286,642.00 |
| Dec 31, 2022 | 286,642.00 |
| Sep 30, 2022 | 271,037.00 |
| Sep 30, 2022 | 271,037.00 |
| Jun 30, 2022 | 232,718.00 |
| Jun 30, 2022 | 232,718.00 |
| Mar 31, 2022 | 154,834.00 |
| Mar 31, 2022 | 154,834.00 |
| Dec 31, 2021 | 267,268.00 |
| Dec 31, 2021 | 267,268.00 |
| Sep 30, 2021 | 191,075.00 |
| Sep 30, 2021 | 191,075.00 |
| Jun 30, 2021 | 117,187.00 |
| Jun 30, 2021 | 117,187.00 |
| Mar 31, 2021 | 79,397.00 |
| Mar 31, 2021 | 79,397.00 |